SUDEEP PHARMA LIMITED

Manufactures and sells specialty ingredients and pharmaceutical, food and nutrition excipients through two reporting segments. The Pharmaceutical, Food and Nutrition segment earned ₹362.6 crore in FY26, supplying ingredients used in pharma, food, and nutrition formulations. The Speciality Ingredients segment earned ₹279.6 crore, having grown 62% year-on-year, and includes the newly launched AbsorBis bisglycinate brand targeting roughly a $1 billion global market at about 4x the realisation of the core portfolio. Materials are the largest cost line at 42% of revenue, with management citing phosphoric and sulphuric acid inflation as a key FY26 headwind, followed by other opex at 22% and employee costs at 8.1%. The company is also building a battery-grade iron phosphate business for LFP batteries, with a Phase 1 plant of 25,000 MT per year at Dahej targeted for April 2027 commissioning, a 42-customer qualification pipeline, 6 customers in commercial validation, and an initial 700 MT purchase order. The company listed on the exchanges on 28 November 2025 and acquired 85% of Ireland-based Nutrition Supplies Services to strengthen its European presence.